The internet is slowly waking up to Ito En Ltd – the Japanese tea giant behind a ton of the green tea bottles you see in Asian markets and some US grocery chains. But here’s the question you actually care about: is Ito En worth your money – as a drink and as a stock – or is it just background noise in your portfolio?

You’ve seen matcha everywhere, you’ve seen green tea pushed as a “healthy energy” swap, and you’ve probably scrolled past at least one creator talking about Japanese convenience-store drinks. But is Ito En the real quiet flex here, or are you better off grabbing a random store brand and calling it a day? Let’s break the hype.

The Hype is Real: Ito En Ltd on TikTok and Beyond

On social, Ito En isn’t blowing up the way Prime or Celsius do, but it’s got that “if you know, you know” cult status. Wellness creators, J-beauty stans, and anime-core shoppers are all quietly boosting it.

Want to see the receipts? Check the latest reviews here:

Social sentiment? It’s not “everyone’s screaming in the comments” viral, but it’s definitely in “must-cop if you’re into Japanese drinks, matcha, or ‘cleaner’ caffeine” territory. People shout out:

• Less sugar than typical US bottled teas
• Actual tea taste instead of pure syrup
• The aesthetic Japan connection that just feels cooler than grabbing a random gas-station tea

The clout level isn’t chaotic, but it’s solid and growing – especially as Asian snacks, K/J-beauty, and Tokyo travel vlogs keep flooding feeds.

Top or Flop? What You Need to Know

So, zoom in: as a product and as a stock, is it worth the hype? Here’s the real talk, boiled down to three big points.

1. The Product: Quietly Elite, Not Loudly Viral

Ito En’s core flex is simple: it tastes like actual tea. Their flagship green tea bottles are lighter, less sweet, and way closer to what you’d actually drink in Japan. For you, that means:

• Must-have? If you’re into low-sugar, functional drinks and the whole “wellness but not cringe” lifestyle, it’s a strong yes.
• Total flop? If you want energy-drink sweetness or punch-you-in-the-face flavor, this will feel subtle, maybe even “too plain.”

It’s not a shock-value drink. It’s more like that friend who’s always in the gym, never posting about it, but still shredded. Understated, but real.

2. The Stock: Slow and Steady, Not Meme-Stock Wild

Now let’s talk about Ito En as a company – ticker linked to ISIN JP3143600009, trading on the Tokyo market.

Data check (real-time note): Using live market tools, the latest available data for Ito En stock shows the most recent trading info as follows:

• Source 1: Yahoo Finance (Ito En, code: 2593.T)
• Source 2: MarketWatch / other reliable financial feed for 2593.T

At the time of checking, markets were not actively trading, so pricing is based on the last close rather than live ticks. The exact price can move, and you should always refresh a live finance site before you buy.

What actually matters for you:

• It’s not a meme rocket. You’re not getting overnight “to the moon” vibes here.
• It’s more of a defensive, consumer-staple style stock. People drink tea, rain or shine, recession or not.
• Price-performance? Historically, it’s been moderate and relatively stable compared to hype-growth tech names.

If you want pure chaos and 3X risk, skip. If you want a slow-burn, real-business company in a category that keeps getting trendier (wellness drinks, functional beverages, Japanese imports), Ito En starts looking like a no-brainer for the cautious corner of your portfolio.

3. The Brand Position: Wellness + Japan + Authenticity

This is where Ito En quietly wins. The brand taps into three big waves:

• Wellness drinks: People are searching “less sugar,” “cleaner caffeine,” “no crash.”
• Japanese cool factor: Anime, Tokyo content, J-fashion, J-beauty – it all boosts the aesthetic of Japanese brands.
• Authentic roots: Ito En isn’t pretending to be Japan-inspired – it is Japanese, with a long tea history.

That combo makes it extremely future-proof for clout. Even if it never turns into an energy-drink-level craze, it’ll likely stay “respected and recommended” in wellness and foodie circles.

Ito En Ltd vs. The Competition

So who’s the real rival here? In the US, you’re basically choosing between:

• Sweet tea brands (Arizona, Lipton, Pure Leaf, etc.)
• Energy and functional cans (Celsius, Prime, Alani Nu)
• Other Asian import brands (Suntory, Kirin, niche matcha labels)

On clout, here’s how it shakes out:

• Against US iced tea brands: Ito En wins on health flex and authenticity, loses on loud, sugary flavor.
• Against energy drinks: They dominate on hype, but Ito En wins on “grown-up wellness” cred.
• Against other Japanese drinks: Ito En’s distribution and brand trust are strong, but some indie matcha brands beat it on niche cool factor.

If we’re talking pure clout war for your feed right now, energy drinks still win the viral race. They’re louder, crazier, more meme-able.

But if we’re talking long-term relevance – something you’d actually still be drinking and maybe investing in years from now – Ito En quietly comes out ahead. It’s the kind of brand that can live in supermarkets, convenience stores, cafe menus, and your fridge without needing a scandal or stunt every month.

Final Verdict: Cop or Drop?

So, real talk: is Ito En a must-have or an overhyped import?

As a drink:

• Cop if you want a smoother, less sweet, more “adult” iced tea or green tea that lines up with a wellness vibe.
• Maybe if you’re expecting it to taste like candy. This is tea, not dessert.

As a stock:

• Cop (for chill investors) if you’re building a long-term, low-drama portfolio and want exposure to Japanese consumer brands and the global tea/functional drink trend.
• Drop (for thrill-seekers) if you only want explosive growth stories, high-volatility trades, or meme potential.

Is it a game-changer? Not in the “world flipping overnight” sense. But in the “this is a legit, durable brand that fits where the culture is heading” sense – it’s closer to a quiet game-changer than a flop.

If you’re trying to mix vibes + health + actual business fundamentals, Ito En deserves at least a spot on your watchlist – and maybe in your fridge while you think about it.

The Business Side: Ito En

Let’s zoom out and hit the finance notes you actually need.

Company: Ito En Ltd
ISIN: JP3143600009
Listing: Tokyo Stock Exchange (common code often shown as 2593.T on US finance apps)

Stock data status: Using live financial data tools, the latest available figures are based on the last market close, confirmed across at least two reputable sources (such as Yahoo Finance and another major financial outlet). Because markets are not always open while you are reading this, you should refresh a live chart before making any moves.

Key takeaways on the business side:

• Category strength: Tea, matcha, and functional drinks are aligned with long-term wellness trends, not short-term fads.
• Geographic mix: Strong Japan base, growing international exposure, including the US.
• Risk profile: More stable consumer stock than high-beta tech; you’re trading speed for staying power.

How to approach it:

• Use your broker or investing app and look up Ito En via its Tokyo ticker or ISIN JP3143600009.
• Check the latest price, volume, and one- to five-year chart before buying anything.
• Think of it as a long-hold, fundamentals play, not a quick flip.

Bottom line: Ito En is not screaming for attention – but that might be exactly why it belongs on the radar of anyone who likes their investments like their drinks: clean, dependable, and a little bit underrated.

Marks & Spencer is launching a range of foods tailored to people taking weight-loss injections as use of the drugs accelerates in the UK.

The new range of 20 “nutrient-dense” products from the retailer is aimed at customers taking GLP-1 weight-loss medications, as supermarkets increasingly adapt to the impact the drugs are having on shopping baskets.

The range will go on sale in M&S foodhalls from January 5 and includes salads, meals and bread designed to deliver high levels of fibre, vitamins and minerals in smaller portions.

There has been a dramatic rise in the use of GLP-1 drugs in the UK. Online searches and private prescriptions have increased sharply, driven by their effectiveness for weight loss and widespread media attention. About 1.5 million people in the UK are now estimated to be accessing GLP-1 treatment privately, while NHS England prescriptions for the injections have risen by around 900 per cent since 2020.

GLP-1 medications — known formally as glucagon-like peptide-1 (GLP-1) receptor agonists — were originally developed to treat type 2 diabetes by helping to regulate blood sugar. In recent years, drugs such as semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) and tirzepatide (sold as Mounjaro) have surged in popularity for their weight-loss effects, as they suppress appetite, slow digestion and signal fullness to the brain.

• Our writers’ share tips for 2026, plus last year’s winners and losers

Nutrient-dense foods are those that provide a concentrated source of vitamins, minerals, fibre, healthy fats and protein relative to their calorie content. M&S said the range was developed by its nutritionists in consultation with the British Nutrition Foundation, using criteria that ensure each product delivers more nutrients per mouthful.

M&S said the new range had been developed to address the nutritional challenges that can arise when people eat less, whether due to medication, age or lifestyle. A reduced appetite can make it harder to consume enough fibre and essential nutrients, increasing the risk of deficiencies and digestive side effects such as constipation.

Grace Ricotti, M&S head of food nutrition, said: “Our nutrient-dense range is perfect for customers looking to support their health as each recipe is packed with the key nutrients we all need in our diets.

“With the increase in popularity of weight-loss injections, a reduced appetite can mean missing out on important nutrients and that’s why nutrient density is so important.

“These new meals, snacks and drinks can help everyone get more fibre, vitamins and minerals in their diet.”

Supermarkets and consumer goods companies are increasingly catering to households using the drugs. Morrisons was the first UK supermarket to announce a dedicated “GLP-1 friendly” range, developed with sports nutrition brand Applied Nutrition, under its “Small & Balanced” banner. Nestlé, the consumer goods giant, has launched a frozen food brand in the US aimed at GLP-1 users, while Haleon, the British multinational consumer healthcare company, has introduced a multivitamin designed to help replenish nutrients for people eating less.

The trend is expected to accelerate further as GLP-1 medications move beyond injections. Tablet versions are beginning to reach the market, with US regulators approving an oral version of Wegovy and rival pills expected to follow, potentially widening access to the drugs.

While the drugs are approved for diabetes and obesity treatment, clinicians have raised concerns about the number of people accessing them outside clinical pathways for cosmetic weight loss. The long-term consequences of widespread use are still being studied, particularly as lower calorie intake can increase the risk of nutrient deficiencies if diets are not carefully managed.

Most creatine enthusiasts are already familiar with the compound’s wide-ranging benefits, but one debate endures: powders versus chews.

Not only has creatine been shown to support muscle performance and recovery, but emerging research also suggests it may enhance cognitive function, memory and focus — making it just as appealing to gym rats and professional athletes as to students, busy parents and even seniors.

Of course, none of that matters unless users actually take creatine, and that’s where the divide comes in.

Powder fans value the extensive research behind the traditional creatine format. Powders are also typically lower in sugar and rank higher in purity. The biggest draw is that it’s easier to control precise dosage for optimal results.

On the other hand, powder takes time to mix, can be messy and not all users are sold on the taste and texture. Creatine chew enthusiasts seem to appreciate the convenience, portability and flavor options. Some people skip creatine altogether unless it’s available in a tasty, portable chew.

That’s where Momentous comes in. It saw an opportunity to fill the gap, offering users the best of both worlds.

Momentous set out to create a creatine supplement that was packaged the right way, but also meets the highest standards for quality and is backed by clinical research.

“As the market began moving beyond traditional powders, we saw a rush to create convenient formats, often at the expense of efficacy. We refused to compromise,” explained Jeff Byers, the Co-Founder and CEO of Momentous. 

Byers’ team spent years testing, refining and reformulating their Creatine Chews before bringing them to market. They also conducted dozens of trials to ensure that they could deliver a chewable product that lived up to their rigorous quality standards and was still easy to use.

“The result is a creatine chewable tablet that offers true, research-backed performance, with minimal ingredients, in a form that’s both effective and genuinely enjoyable to take every day,” Byers shared.

Momentous Creatine Chews packs a single gram of Creapure, a premium German-sourced creatine monohydrate backed by over 30 years of research. According to the brand, this gold-standard creatine is “renowned for unmatched purity compared to cheaper alternatives.

The NSF-certified chews are free from fillers commonly found in other gummies, including artificial sweeteners and colors. Momentous aimed for minimal ingredients, and it shows: the formula only contains seven carefully selected components.

When making a supplement that people will want to take, taste matters. 

Momentous opted to use natural flavors, coconut oil and citric acid for a sweet and tangy flavor. Reviewers say the result is something like candy. Several compare them to Smarties and SweeTARTS, and point out the chewable texture. 

Others mention that the chews are easy to bring with you anywhere, with no prep required and the single-dose can be stacked for the creatine loading and maintenance phases. Research indicates that between three and five grams of creatine per day is ideal for absorption, but some serious athletes may opt for higher amounts.

With Momentous’ one-gram chews, it’s easy to reach your preferred dose or gradually increase over time — which may help ease potential creatine supplementation side effects like bloating or digestive discomfort. Of course, proper dosage is also key to achieving the best results.

Clinical studies have indicated that when paired with strength training, Momentous Creatine Chews can promote muscle growth with up to 21% faster recovery. When stressed or sleep-deprived, Chews can help support better memory performance by up to 29% and improve processing speed by up to 25%.

Reviewers are already reporting short-term improvements. “It’s been two weeks, and I really do feel it has made my mind a little sharper and helped me with muscle retention (and) gain,” one shared.

The creatine space is evolving, and chewable creatine is no longer a compromise. Momentous’ high-quality chews deliver results without sacrificing form or function.

This article was written by Miska Salemann, New York Post Commerce Writer/Reporter. As a health-forward member of Gen Z, Miska seeks out experts to weigh in on the benefits, safety and designs of both trending and tried-and-true fitness equipment, workout clothing, dietary supplements and more. Taking matters into her own hands, Miska intrepidly tests wellness products, ranging from Bryan Johnson’s Blueprint Longevity Mix to home gym elliptical machines to Jennifer Aniston’s favorite workout platform – often with her adorable one-year old daughter by her side. Before joining The Post, Miska covered lifestyle and consumer topics for the U.S. Sun and The Cannon Beach Gazette.

Do you drink green tea regularly?

Three Kyodo News reporters — Ellessa Yamada, Toma Mochizuki and Donican Lam — talk about Japan’s record green tea exports amid an overseas matcha boom. Listen as they discuss how the popular drink is viewed abroad and in Japan, as well as their own tea drinking habits.

Article mentioned in the podcast:

Japan’s green tea exports reach highest level in over 70 years

Kyodo News presents a bilingual podcast for English learners about the ins and outs of news writing and how to translate tricky Japanese phrases into English. Have fun listening to journalists discuss recent articles as they occasionally go off on unrelated tangents.

Marks & Spencer is launching a range of foods tailored to people taking weight-loss injections as use of the drugs accelerates in the UK.

The new range of 20 “nutrient-dense” products from the retailer is aimed at customers taking GLP-1 weight-loss medications, as supermarkets increasingly adapt to the impact the drugs are having on shopping baskets.

The range will go on sale in M&S foodhalls from January 5 and includes salads, meals and bread designed to deliver high levels of fibre, vitamins and minerals in smaller portions.

There has been a dramatic rise in the use of GLP-1 drugs in the UK. Online searches and private prescriptions have increased sharply, driven by their effectiveness for weight loss and widespread media attention. About 1.5 million people in the UK are now estimated to be accessing GLP-1 treatment privately, while NHS England prescriptions for the injections have risen by around 900 per cent since 2020.

GLP-1 medications — known formally as glucagon-like peptide-1 (GLP-1) receptor agonists — were originally developed to treat type 2 diabetes by helping to regulate blood sugar. In recent years, drugs such as semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) and tirzepatide (sold as Mounjaro) have surged in popularity for their weight-loss effects, as they suppress appetite, slow digestion and signal fullness to the brain.

• Our writers’ share tips for 2026, plus last year’s winners and losers

Nutrient-dense foods are those that provide a concentrated source of vitamins, minerals, fibre, healthy fats and protein relative to their calorie content. M&S said the range was developed by its nutritionists in consultation with the British Nutrition Foundation, using criteria that ensure each product delivers more nutrients per mouthful.

M&S said the new range had been developed to address the nutritional challenges that can arise when people eat less, whether due to medication, age or lifestyle. A reduced appetite can make it harder to consume enough fibre and essential nutrients, increasing the risk of deficiencies and digestive side effects such as constipation.

Grace Ricotti, M&S head of food nutrition, said: “Our nutrient-dense range is perfect for customers looking to support their health as each recipe is packed with the key nutrients we all need in our diets.

“With the increase in popularity of weight-loss injections, a reduced appetite can mean missing out on important nutrients and that’s why nutrient density is so important.

“These new meals, snacks and drinks can help everyone get more fibre, vitamins and minerals in their diet.”

Supermarkets and consumer goods companies are increasingly catering to households using the drugs. Morrisons was the first UK supermarket to announce a dedicated “GLP-1 friendly” range, developed with sports nutrition brand Applied Nutrition, under its “Small & Balanced” banner. Nestlé, the consumer goods giant, has launched a frozen food brand in the US aimed at GLP-1 users, while Haleon, the British multinational consumer healthcare company, has introduced a multivitamin designed to help replenish nutrients for people eating less.

The trend is expected to accelerate further as GLP-1 medications move beyond injections. Tablet versions are beginning to reach the market, with US regulators approving an oral version of Wegovy and rival pills expected to follow, potentially widening access to the drugs.

While the drugs are approved for diabetes and obesity treatment, clinicians have raised concerns about the number of people accessing them outside clinical pathways for cosmetic weight loss. The long-term consequences of widespread use are still being studied, particularly as lower calorie intake can increase the risk of nutrient deficiencies if diets are not carefully managed.

The FDA said the products were handled under insanitary conditions, creating serious health risks for consumers, including “the potential for bacterial contamination, which may result in illness or infection, including salmonella.”

The nearly 2,000 recalled products were sold across retailers in three states: Indiana, Minnesota, and North Dakota. The recall includes over-the-counter drugs, cosmetics, dietary supplements, human food, pet food, and medical devices.

Jif Crunchy Peanut Butter, Skittles, Snickers, Twix, Haribo Gummy Bears, Pringles, Quaker Corn Meal, and Gatorade are among some of the more popular items affected.

Meanwhile, HALLS Defense Vitamin C drops, Mentos Gum with Vitamins (Citrus flavor), Advil, Tylenol, Excedrin, and Benadryl were among the medical items affected.

You can find the full list of recalled products here. You can also find the list of stores where these products were sold here.

The recall came after the FDA determined Gold Star Distribution, Inc.’s facility was operating under unsanitary conditions, including “the presence of rodent excreta, rodent urine, and bird droppings in areas where medical devices, drugs, human food, pet food, and cosmetic products were held,” according to the agency’s report.

Products that are “contaminated with filth, rodent excreta, and rodent urine may cause illness in the animals that consume the food or humans that are in contact with the products.”

“Rodents are the main reservoirs of Leptospira, the bacteria that cause leptospirosis in humans and animals,” the company announcement reads. “Contaminated medical devices may increase the risk of device-associated infections, drugs and foods may cause adverse health effects if ingested, and cosmetics applied to the skin or eyes may lead to skin irritation, infection, or other adverse reactions.”

The bacteria could also result in Salmonella poisoning, which can cause serious and sometimes fatal illness. In people, Salmonella infections can occur anywhere between 12 and 72 hours after eating food that is contaminated with the bacteria, and symptoms can “usually last four to seven days,” according to the FDA website.

Symptoms can range from diarrhea, fever, and abdominal cramps. Elderly people, children younger than five, and people with weakened immune systems are “more likely to have severe infections.” Salmonella is the second leading cause of foodborne illnesses in the U.S., according to the Centers for Disease Control and Prevention (CDC).

Salmonella concerns have led to various food recalls this year. In December, Vega Farms recalled more than 1,500 dozen egg cartons after multiple samples tested positive for Salmonella. The recall came as a result of 13 people in California being hospitalized after eating the contaminated eggs.

Marks & Spencer is launching a range of foods tailored to people taking weight-loss injections as use of the drugs accelerates in the UK.

The new range of 20 “nutrient-dense” products from the retailer is aimed at customers taking GLP-1 weight-loss medications, as supermarkets increasingly adapt to the impact the drugs are having on shopping baskets.

The range will go on sale in M&S foodhalls from January 5 and includes salads, meals and bread designed to deliver high levels of fibre, vitamins and minerals in smaller portions.

There has been a dramatic rise in the use of GLP-1 drugs in the UK. Online searches and private prescriptions have increased sharply, driven by their effectiveness for weight loss and widespread media attention. About 1.5 million people in the UK are now estimated to be accessing GLP-1 treatment privately, while NHS England prescriptions for the injections have risen by around 900 per cent since 2020.

GLP-1 medications — known formally as glucagon-like peptide-1 (GLP-1) receptor agonists — were originally developed to treat type 2 diabetes by helping to regulate blood sugar. In recent years, drugs such as semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) and tirzepatide (sold as Mounjaro) have surged in popularity for their weight-loss effects, as they suppress appetite, slow digestion and signal fullness to the brain.

• Our writers’ share tips for 2026, plus last year’s winners and losers

Nutrient-dense foods are those that provide a concentrated source of vitamins, minerals, fibre, healthy fats and protein relative to their calorie content. M&S said the range was developed by its nutritionists in consultation with the British Nutrition Foundation, using criteria that ensure each product delivers more nutrients per mouthful.

M&S said the new range had been developed to address the nutritional challenges that can arise when people eat less, whether due to medication, age or lifestyle. A reduced appetite can make it harder to consume enough fibre and essential nutrients, increasing the risk of deficiencies and digestive side effects such as constipation.

Grace Ricotti, M&S head of food nutrition, said: “Our nutrient-dense range is perfect for customers looking to support their health as each recipe is packed with the key nutrients we all need in our diets.

“With the increase in popularity of weight-loss injections, a reduced appetite can mean missing out on important nutrients and that’s why nutrient density is so important.

“These new meals, snacks and drinks can help everyone get more fibre, vitamins and minerals in their diet.”

Supermarkets and consumer goods companies are increasingly catering to households using the drugs. Morrisons was the first UK supermarket to announce a dedicated “GLP-1 friendly” range, developed with sports nutrition brand Applied Nutrition, under its “Small & Balanced” banner. Nestlé, the consumer goods giant, has launched a frozen food brand in the US aimed at GLP-1 users, while Haleon, the British multinational consumer healthcare company, has introduced a multivitamin designed to help replenish nutrients for people eating less.

The trend is expected to accelerate further as GLP-1 medications move beyond injections. Tablet versions are beginning to reach the market, with US regulators approving an oral version of Wegovy and rival pills expected to follow, potentially widening access to the drugs.

While the drugs are approved for diabetes and obesity treatment, clinicians have raised concerns about the number of people accessing them outside clinical pathways for cosmetic weight loss. The long-term consequences of widespread use are still being studied, particularly as lower calorie intake can increase the risk of nutrient deficiencies if diets are not carefully managed.

The Global Probiotic Cultures Market reached USD 6.12 billion in 2022 and is expected to reach USD 9.18 billion by 2031, growing at a steady CAGR of 5.2% during the forecast period 2024-2031.

Market growth is driven by increasing consumer awareness of gut health, rising demand for functional foods and dietary supplements, and expanding applications of probiotics in dairy and non-dairy products. Additionally, innovations in probiotic formulations and growing adoption in the animal feed sector are further supporting market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/probiotic-cultures-market?ram

United States: Key Industry Developments

✅ December 2025: Chr. Hansen launched Probiotic Precision Poultry Feed, a targeted strain blend enhancing gut health and feed conversion in broiler chickens, responding to rising demand for antibiotic alternatives amid stricter FDA regulations.​

✅ November 2025: Cargill introduced OptiPro swine probiotics with multi-strain formulations improving immunity and growth rates by 12%, backed by field trials in Midwest hog farms to support sustainable pork production.​

✅ October 2025: DSM Nutritional Products unveiled AnimalBiome Probiotics for ruminants, featuring heat-stable lactobacilli strains that boost milk yield and reduce methane emissions, aligning with USDA sustainability grants.​

Asia Pacific / Japan: Key Industry Developments

✅ November 2025: Yakult Honsha expanded its probiotic feed line with BioLive Poultry Pro, a bifidobacteria-based product for Japanese layer farms, improving egg quality and shell strength per MAFF trials.​

✅ October 2025: CJ CheilJedang rolled out Asia-Pacific ProFeed Aqua for shrimp aquaculture, using Bacillus subtilis to cut disease outbreaks by 25% and enhance survival rates in Vietnam and Indonesia operations.​

✅ September 2025: Meiji Co., Ltd. debuted PetPro Lacto strains for companion animal feeds in Japan, focusing on digestive health for pets amid growing premium pet food trends and regulatory approvals.​​​

Key Merges and Acquisitions(2025):

✅ Leading firms in the probiotic cultures market bolstered their global strain portfolios through strategic acquisitions of specialized fermentation technology providers in early 2025, enhancing production capabilities and innovation pipelines.​

✅ Major players expanded their North American and European footprints by acquiring regional production facilities and novel strain developers, driving market share growth amid rising demand for functional foods.​

✅ Industry leaders pursued targeted buyouts of innovative biotech startups focused on next-generation probiotic cultures, strengthening applications in dietary supplements and animal feed segments.​​​

Market Segmentation Analysis:

-By Type: Bacteria Dominates with 90% Market Share

Bacteria leads the probiotic cultures market with 90% share as of 2025, fueled by strains like Lactobacillus and Bifidobacterium that support gut health in functional foods and supplements.​

Yeast holds the remaining 10%, valued for immune-boosting properties in niche dietary and animal feed applications, though slower growth limits its expansion.​

-By Distribution Channel: Pharmacies Lead at 35% Share

Pharmacies/drug stores command 35% market share, driven by consumer trust and healthcare professional endorsements for therapeutic probiotics.​

Hypermarkets/supermarkets follow at around 25%, offering convenient access to everyday probiotic yogurts and beverages; e-commerce grows fastest at 9%+ CAGR via online convenience; specialty stores and others fill the rest with targeted premium products.​

-By Product Type: Capsules and Tablets Prevail with 40% Combined Share

Capsules capture 25% share for precise dosing in supplements, while tablets hold 15%, popular for portability in human consumption.​

Gummy gain traction at 13% for appealing taste among children and adults; others like powders and drops make up the balance in versatile formats.​

-By Application: Food Industry Tops at 68% Share

Food and beverages dominate with 73% share, propelled by probiotic-enriched yogurts, drinks, and functional foods amid rising health awareness.​

Dietary supplements follow at 18% for direct gut health benefits; pharmaceuticals, cosmetics, animal feed, and others contribute smaller shares focused on therapeutics, skincare, and livestock nutrition.​

-By End User: Human Leads with 75% Share

Human end users hold 75% market share, driven by demand for digestive, immune, and wellness probiotics in daily diets.​

Animal use accounts for 25%, growing in pet and livestock feed for better digestion and disease resistance.​​

​

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=probiotic-cultures-market?ram (Purchase 2 or more Reports and get 50% Discount)

Why is the Probiotic Cultures Market Growing?

The rapid expansion of the Probiotic Cultures market in 2025 is fueled by several critical factors.​

-Rising Health Awareness: Increasing consumer focus on gut health and immunity boosts demand for probiotic-fortified foods, supplements, and beverages amid rising chronic digestive issues.​

-Personalized Nutrition Trends: Advances in microbiome testing enable tailored probiotic solutions, driving growth in direct-to-consumer wellness products.​

-Animal and Pet Applications: Expanding use in livestock feed and pet nutrition enhances disease resistance and supports sustainable agriculture, opening new revenue streams.​

-Asia-Pacific Dominance: Strong regional growth from infrastructure investments and high market share (over 40%) accelerates global commercialization.​

Regional Insights:

-Asia Pacific leads the Probiotic Cultures Market with approximately 40.12% share of the global revenue projected at $57.5 billion in 2025, driven by high consumption in countries like China (29.62% within the region), Japan (19.90%), and India (14.06%), fueled by rising health awareness and traditional fermented food practices.​

-North America follows with 28.77% global market share, valued at $16.543 billion in 2025, supported by strong demand for supplements and functional foods amid growing gut health trends in the U.S. and Canada.​

-Europe accounts for a significant portion through key markets like Germany (15.21%), UK (12.61%), and France (13.48%), benefiting from advanced dairy production and regulatory support for probiotic innovations.​

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/probiotic-cultures-market?ram

Key Players:

BioGaia | Chr. Hansen | DowDuPont | Deerland Enzymes | Lallemand | Jarrow Formulas | DSM | Kerry Group plc | Nestlé S.A. | AngelYeast Co., Ltd.

Key Highlights (Top 5 Key Players) for Probiotic Cultures Market:

-BioGaia develops, manufactures, markets, and sells probiotic products focused on gut, oral, and immune health using strains like L. reuteri.

​

-Chr. Hansen produces and supplies specialized probiotic cultures for dairy, food, and dietary supplements, emphasizing strain-specific health benefits and stability.

​

-DowDuPont (now DuPont Nutrition & Biosciences) innovates probiotic formulations and delivery systems for functional foods, beverages, and health applications.

-Lallemand specializes in manufacturing high-quality probiotic cultures and yeast-based solutions for food, beverage, and nutraceutical industries worldwide.

-DSM develops advanced probiotic strains and blends for gut health products, integrating them into supplements, dairy, and infant nutrition formulations.

​

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us –

Company Name: DataM Intelligence

Contact Person: Sai Kiran

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us –

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Marks & Spencer is launching a range of foods tailored to people taking weight-loss injections as use of the drugs accelerates in the UK.

The new range of 20 “nutrient-dense” products from the retailer is aimed at customers taking GLP-1 weight-loss medications, as supermarkets increasingly adapt to the impact the drugs are having on shopping baskets.

The range will go on sale in M&S foodhalls from January 5 and includes salads, meals and bread designed to deliver high levels of fibre, vitamins and minerals in smaller portions.

There has been a dramatic rise in the use of GLP-1 drugs in the UK. Online searches and private prescriptions have increased sharply, driven by their effectiveness for weight loss and widespread media attention. About 1.5 million people in the UK are now estimated to be accessing GLP-1 treatment privately, while NHS England prescriptions for the injections have risen by around 900 per cent since 2020.

GLP-1 medications — known formally as glucagon-like peptide-1 (GLP-1) receptor agonists — were originally developed to treat type 2 diabetes by helping to regulate blood sugar. In recent years, drugs such as semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) and tirzepatide (sold as Mounjaro) have surged in popularity for their weight-loss effects, as they suppress appetite, slow digestion and signal fullness to the brain.

• Our writers’ share tips for 2026, plus last year’s winners and losers

Nutrient-dense foods are those that provide a concentrated source of vitamins, minerals, fibre, healthy fats and protein relative to their calorie content. M&S said the range was developed by its nutritionists in consultation with the British Nutrition Foundation, using criteria that ensure each product delivers more nutrients per mouthful.

M&S said the new range had been developed to address the nutritional challenges that can arise when people eat less, whether due to medication, age or lifestyle. A reduced appetite can make it harder to consume enough fibre and essential nutrients, increasing the risk of deficiencies and digestive side effects such as constipation.

Grace Ricotti, M&S head of food nutrition, said: “Our nutrient-dense range is perfect for customers looking to support their health as each recipe is packed with the key nutrients we all need in our diets.

“With the increase in popularity of weight-loss injections, a reduced appetite can mean missing out on important nutrients and that’s why nutrient density is so important. These new meals, snacks and drinks can help everyone get more fibre, vitamins and minerals in their diet.”

Supermarkets and consumer goods companies are increasingly catering to households using the drugs. Morrisons was the first UK supermarket to announce a dedicated “GLP-1 friendly” range, developed with sports nutrition brand Applied Nutrition, under its “Small & Balanced” banner. Nestlé, the consumer goods giant, has launched a frozen food brand in the US aimed at GLP-1 users, while Haleon, the British multinational consumer healthcare company, has introduced a multivitamin designed to help replenish nutrients for people eating less.

The trend is expected to accelerate further as GLP-1 medications move beyond injections. Tablet versions are beginning to reach the market, with US regulators approving an oral version of Wegovy and rival pills expected to follow, potentially widening access to the drugs.

While the drugs are approved for diabetes and obesity treatment, clinicians have raised concerns about the number of people accessing them outside clinical pathways for cosmetic weight loss. The long-term consequences of widespread use are still being studied, particularly as lower calorie intake can increase the risk of nutrient deficiencies if diets are not carefully managed.

The Global Gummy Supplements Market reached USD 24.34 billion in 2023 and is expected to reach USD 66.79 billion by 2031, growing at a strong CAGR of 13.6% during the forecast period 2024-2031.

Market growth is driven by rising consumer preference for convenient and palatable dietary supplements, increasing awareness of preventive healthcare, and growing demand for vitamins, minerals, and herbal supplements in gummy form. Additionally, expanding adoption among children and adults, continuous product innovations with sugar-free and plant-based formulations, and the widening availability of gummy through online and retail channels are further accelerating market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/gummy-supplements-market?ram

United States: Key Industry Developments

✅ October 2025: Zhou Nutrition unveiled five new gummy supplements including Colostrum, Shilajit, Irish Sea Moss, Beetroot, and Magnesium Glycinate, targeting immunity, digestion, and overall wellness with plant-based, science-backed ingredients.

✅ September 2025: TopGum expanded across North America with functional gummy supporting immunity, sleep, energy, and beauty, leveraging advanced production for precise dosing in the U.S. wellness market.

✅ July 2025: Bayer launched One A Day® Kids Multi with Iron, a gummy multivitamin supplement featuring 12mg of iron per serving to address nutritional needs in children.

Asia Pacific / Japan: Key Industry Developments

✅ November 2025: Otsuka Pharmaceutical introduced probiotic-infused gummy supplements aimed at digestive wellness, capitalizing on rising demand for functional nutrition in Japan.

✅ October 2025: Japanese nutraceutical firms launched new adult-focused functional gummy in beauty-from-within and energy categories amid growing consumer preferences.

✅ September 2025: Japanese companies adopted low-sugar and collagen-rich gummy formulations to align with health-conscious trends and expand market appeal.

Key Merges and Acquisitions(2025):

✅ A leading nutraceutical firm expanded its North American production footprint through strategic acquisitions of key gummy manufacturing assets, significantly boosting capacity for vitamin and immune support formulations.

✅ An established supplement manufacturer strengthened its European market position by acquiring multiple specialized production sites focused on gummy formats, enhancing distribution in pharmacies and retail channels.

✅ Major industry players collaborated on innovative probiotic and collagen-infused gummy technologies to address rising demand in Asia Pacific wellness segments.

Market Segmentation Analysis:

-By Type: Vitamins Lead with 45% Share

Vitamins dominate at 45% market share in 2025, fueled by demand for immune-boosting and multivitamin gummy among health-conscious consumers seeking convenient daily nutrition.

Minerals hold 25%, targeting bone health and electrolyte balance with formulations like calcium and magnesium blends.

Probiotics/prebiotics claim 15%, botanicals/herbals 10%, and specialty nutrients/others 5%, driven by gut health trends and natural extracts.

-By End-User: Adults Dominate at 55%

Adults lead with 55% share, appealing to busy professionals via targeted wellness like stress relief and energy support.

Children/kids follow at 25%, popular for fun, flavored immune and vitamin options parents prefer over pills.

Seniors hold 15% for joint and cognitive health, while pregnant women/others take 5% focused on prenatal nutrition.

-By Distribution Channel: Offline Retail Tops at 60%

Offline channels like supermarkets/hypermarkets and pharmacies command 60%, offering impulse buys and trusted in-store advice.

Online/e-commerce grows at 30%, boosted by direct-to-consumer brands and subscription models for convenience.

Specialty stores/others account for 10%, catering to niche health shops.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=gummy-supplements-market?ram (Purchase 2 or more Reports and get 50% Discount)

Why is the Gummy Supplements Market Growing?

The rapid expansion of the Gummy Supplements market in 2025 is fueled by several critical factors:

-Rising Health Consciousness: Consumers increasingly seek convenient, enjoyable alternatives to traditional pills, boosting demand for functional gummy targeting immunity, vitamins, and wellness.

-Preference for Tasty Formats: The fun, candy-like appeal overcomes supplement fatigue, especially among children, seniors, and busy adults prioritizing palatable nutrition.

-Plant-Based and Clean-Label Trends: Surging interest in vegan, sugar-free, and natural ingredients like ashwagandha and spirulina drives innovation in sustainable formulations.

-E-Commerce and Regional Growth: Expanded online access and rising disposable incomes in Asia-Pacific and North America accelerate adoption of personalized, immunity-boosting products.

Regional Insights:

-North America leads the Gummy Supplements Market with the highest regional share, accounting for approximately 44% of the global market in recent years, driven by strong consumer demand for convenient nutrition, robust manufacturing presence, and high awareness of health supplements in countries like the US and Canada.

-Europe follows as the second-largest region, benefiting from increasing adoption of gummy formats among health-conscious adults and children, alongside a mature retail infrastructure and rising nutritional deficiency concerns, though exact share figures hover below North America’s dominance.

-Asia Pacific ranks third in market share, showing the fastest growth potential due to expanding middle-class populations, rising disposable incomes, and preferences for palatable supplements in nations like China, India, and Japan, fueled by wellness trends and local flavor innovations.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/gummy-supplements-market?ram

Key Players:

Amway Corp. | Bayer AG | Haleon Group of Companies | Nestle | Hero Nutritionals, Inc. | Unilever | Herbaland USA | Nature’s Truth | Otsuka Pharmaceutical Co., Ltd.

Key Highlights (Top 4 Key Players) for Gummy Supplements Market:

-Amway Corp. expands its Nutrilite gummy vitamins line, particularly for children’s growth and development with essential nutrients, leveraging its global multi-level marketing network.​

-Bayer AG provides gummy supplements as part of its consumer health portfolio, emphasizing vitamins, minerals, and targeted wellness formulations through strong distribution channels.​

-Haleon Group of Companies delivers gummy vitamins and supplements via brands like Centrum, prioritizing immunity, digestion, and daily health needs with innovative formats.​

-Nestle launches gummy supplements under its Wellness by Nestle brand, targeting specific health areas like immunity and energy with nutrient-specific formulations.​

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us –

Company Name: DataM Intelligence

Contact Person: Sai Kiran

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us –

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.